NRSN•benzinga•
NeuroSense Therapeutics Outlines Phase 3 Timeline For PrimeC In ALS, Updates Canadian Regulatory Pathway, Highlights Partnership Talks With A Global Pharmaceutical Company; Says We Have No Immediate Plans For Additional Capital Raising, We Maintain Strong
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 24, 2025 by benzinga